Novartis: JH389 is currently in the European safety trial phase and has not yet submitted trial data to the relevant regulatory authorities.

(Source: Finance News)

          In response to the abnormal fluctuations in the company's stock trading, the company conducted a self-examination of relevant matters and formally consulted the company's controlling shareholder and actual controller for verification.            

On March 26, Meinuohua (603538.SH) announced that the closing price of the company’s stock had a cumulative deviation of over 20% in the increase over three consecutive trading days, which, according to the relevant regulations of the Shanghai Stock Exchange Trading Rules, constitutes an abnormal fluctuation in stock trading.

In response to the abnormal fluctuations in the company’s stock trading, the company conducted a self-examination of relevant matters and formally consulted the company’s controlling shareholder and actual controller for verification. After the company’s self-examination, it has been determined that as of now, the company’s production and operational conditions are normal, there have been no significant changes in the internal and external operating environment, and there have been no major changes in the main business. There is no other significant information that should be disclosed but has not been disclosed. Meanwhile, the company has noted discussions in the market and among certain channels regarding the company’s related research data, clinical trial progress, and future development plans. JH389 is currently in the European safety trial stage and has not yet submitted trial data to the relevant regulatory authorities. The progress of this product’s trial, data submission, and final approval for market launch will require a certain period. Furthermore, during this period of abnormal fluctuations in stock trading, the company’s directors, senior management, controlling shareholders, actual controllers, and their concerted actions, as well as other significant shareholders, have not engaged in buying or selling the company’s stock.

The company warns of related risks, as the closing price of the company’s stock has a cumulative deviation of over 20% in the increase over three consecutive trading days, which constitutes an abnormal fluctuation in stock trading. From March 5, 2026, to the date of this announcement, the company’s stock price has increased by a cumulative 75.30%; in the last five trading days, the company’s stock hit the upper limit four times, accumulating significant trading risks. The latest rolling price-to-earnings ratio for the industry classification “C27 Pharmaceutical Manufacturing Industry” is 27.97 times, while the company’s latest rolling price-to-earnings ratio is 71.75 times, significantly higher than the level of listed companies in the same industry. Investors are urged to pay attention to trading risks in the secondary market, make rational decisions, and invest cautiously.

A wealth of information and precise interpretations can be found in the Sina Finance APP.